Published in J Cancer Res Clin Oncol on August 23, 2009
Intraoperative intraperitoneal chemotherapy with cisplatin in epithelial ovarian cancer. J Gynecol Oncol (2012) 0.93
Small bowel emergency surgery: literature's review. World J Emerg Surg (2011) 0.92
Hyperthermic intraperitoneal chemotherapy with cisplatin and paclitaxel in advanced ovarian cancer: a multicenter prospective observational study. J Gynecol Oncol (2014) 0.88
Intraperitoneal chemotherapy in ovarian cancer: a review of tolerance and efficacy. Cancer Manag Res (2012) 0.86
Outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface dissemination from ovarian neoplasms. Am J Surg (2011) 0.86
Role of mesenchymal cells in the natural history of ovarian cancer: a review. J Transl Med (2014) 0.82
Intraoperative radiotherapy electron boost in advanced and recurrent epithelial ovarian carcinoma: a retrospective study. BMC Cancer (2011) 0.80
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: where are we? World J Gastroenterol (2012) 0.80
Overall morbidity but not mortality is increased in elderly patients following cytoreductive surgery and HIPEC. Langenbecks Arch Surg (2015) 0.78
Cytoreductive surgery and HIPEC in peritoneal recurrent ovarian cancer: experience and lessons learned. Langenbecks Arch Surg (2011) 0.78
Hyperthermic Intra-Thoracic Chemotherapy (HITeC) for the management of recurrent ovarian cancer involving the pleural cavity. Gynecol Oncol Case Rep (2014) 0.78
Experience after 100 patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Gastroenterol (2012) 0.77
A comparative analysis of postoperative pancreatic fistulas after surgery with and without hyperthermic intraperitoneal chemoperfusion. Ann Surg Oncol (2014) 0.77
Surgical treatment of peritoneal carcinomatosis: current treatment modalities. Langenbecks Arch Surg (2013) 0.76
Intraoperative radiotherapy and cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Five consecutive case reports of locally advanced rectal cancer with synchronous peritoneal carcinomatosis. Strahlenther Onkol (2013) 0.75
Cytoreduction (Peritonectomy Procedures) Combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Advanced Ovarian Cancer: Retrospective Italian Multicenter Observational Study of 511 Cases. Ann Surg Oncol (2016) 0.75
Peritoneal metastases from mucinous endocervical adenocarcinoma. Gynecol Oncol Rep (2014) 0.75
Prognostic factors of intraperitoneal chemotherapy for peritoneal carcinomatosis of gastric cancer: A retrospective study from a single center. Oncol Lett (2016) 0.75
Does hyperthermic intraoperative chemotherapy lead to improved outcomes in patients with ovarian cancer? A single center cohort study in 111 consecutive patients. Patient Saf Surg (2012) 0.75
Depth of colorectal-wall invasion and lymph-node involvement as major outcome factors influencing surgical strategy in patients with advanced and recurrent ovarian cancer with diffuse peritoneal metastases. World J Surg Oncol (2013) 0.75
Regional hyperthermia of the abdomen, a pilot study towards the treatment of peritoneal carcinomatosis. Radiat Oncol (2015) 0.75
Cytoreduction and HIPEC in the treatment of "unconventional" secondary peritoneal carcinomatosis. World J Surg Oncol (2015) 0.75
Repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: review of indications and outcomes. J Gastrointest Oncol (2016) 0.75
Critical care management and intensive care unit outcomes following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. World J Crit Care Med (2017) 0.75
A possible dual effect of cigarette smoking on the risk of postmenopausal breast cancer. Eur J Epidemiol (2017) 0.75
Hyperthermic intraperitoneal perfusion chemotherapy and response evaluation in patients with gastric cancer and malignant ascites. Oncol Lett (2017) 0.75
Cancer statistics, 2007. CA Cancer J Clin (2007) 53.49
Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med (2006) 13.63
Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol (2002) 6.51
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol (2006) 4.92
Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol (2006) 4.33
Peritonectomy procedures. Ann Surg (1995) 4.24
Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol (2007) 4.06
Ovarian carcinoma diagnosis. Cancer (2000) 3.12
Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res (1980) 2.48
Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol (2006) 2.23
A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol (2006) 1.96
Treatment goals in ovarian cancer. Int J Gynecol Cancer (2005) 1.75
A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol (2006) 1.69
Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol (2006) 1.67
Cytoreductive surgery and intraperitoneal chemo-hyperthermia for chemo-resistant and recurrent advanced epithelial ovarian cancer: prospective study of 81 patients. World J Surg (2007) 1.66
The role of the diaphragm in lymphatic absorption from the peritoneal cavity. J Anat (1995) 1.62
Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology. Cancer Treat Res (1996) 1.47
Rationale and techniques of intra-operative hyperthermic intraperitoneal chemotherapy. Cancer Treat Rev (2001) 1.33
Intraperitoneal cancer dissemination: mechanisms of the patterns of spread. Cancer Metastasis Rev (2003) 1.28
Recurrent ovarian cancer: evidence-based treatment. J Clin Oncol (2002) 1.27
Towards randomized trials of cytoreductive surgery using peritonectomy and hyperthermic intraperitoneal chemotherapy for ovarian cancer peritoneal carcinomatosis. Gynecol Oncol (2009) 1.23
Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome. Cancer (2007) 1.22
Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum. Int J Gynecol Cancer (2004) 1.04
Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer. Gynecol Oncol (2004) 1.02
Hyperthermic intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer. J Surg Oncol (2008) 1.01
Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy. Int J Hyperthermia (2007) 0.99
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer. World J Surg Oncol (2004) 0.98
Intraoperative hyperthermic intraperitoneal chemotherapy with docetaxel as second-line treatment for peritoneal carcinomatosis of gynaecological origin. Anticancer Res (2003) 0.93
Treatment of peritoneal carcinomatosis with intent to cure. J Surg Oncol (2000) 0.92
Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery. Gynecol Oncol (2007) 0.91
Intraperitoneal chemotherapy for ovarian cancer: 2009 goals. Gynecol Oncol (2009) 0.90
Radical surgery-peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer. J Surg Oncol (2006) 0.88
Secondary surgical cytoreduction for advanced epithelial ovarian cancer. Patient selection and review of the literature. Cancer (1996) 0.88
Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer. World J Surg (2004) 0.87
Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma. Gynecol Oncol (2006) 0.86
Intraperitoneal hyperthermic chemotherapy in ovarian cancer. Int J Gynecol Cancer (2005) 0.85
Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study. Ann Oncol (2007) 0.83
Cytoreductive surgery and modified heated intraoperative intraperitoneal chemotherapy (HIPEC) for advanced and recurrent ovarian cancer -- 12-year single center experience. Eur J Surg Oncol (2009) 0.83
National Cancer Institute-United States strategy regarding intraperitoneal chemotherapy for ovarian cancer. Int J Gynecol Cancer (2008) 0.82
Intra-operative intra-peritoneal chemotherapy with cisplatin in patients with peritoneal carcinomatosis of ovarian cancer. World J Surg Oncol (2009) 0.81
Role of salvage cytoreductive surgery in the treatment of patients with recurrent ovarian cancer after platinum-based chemotherapy. J Obstet Gynaecol Res (2006) 0.80
Intraperitoneal therapy for ovarian cancer: why has it not become standard? J Natl Cancer Inst (2009) 0.80
Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: The experience of National Cancer Institute of Milan. Eur J Surg Oncol (2006) 0.80
Secondary cytoreduction plus oxaliplatin-based HIPEC in platinum-sensitive recurrent ovarian cancer patients: a pilot study. Gynecol Oncol (2009) 0.80
Cytoreductive surgery and intraoperative hyperthermic chemoperfusion for advanced ovarian carcinoma. J Surg Oncol (2005) 0.78
Phase II study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer. Ann Oncol (2003) 0.78
Treatment of recurrent epithelial ovarian cancer with secondary cytoreduction and continuous intraoperative intraperitoneal hyperthermic chemoperfusion (CIIPHCP). Zentralbl Gynakol (2003) 0.77
Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol (2012) 5.06
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol (2009) 3.04
Quality of life after total laparoscopic hysterectomy versus total abdominal hysterectomy for stage I endometrial cancer (LACE): a randomised trial. Lancet Oncol (2010) 2.89
A meta-analysis of unmatched and matched patients comparing video-assisted thoracoscopic lobectomy and conventional open lobectomy. Ann Cardiothorac Surg (2012) 2.61
A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol (2007) 2.06
Systematic review and meta-analysis of transcatheter aortic valve implantation versus surgical aortic valve replacement for severe aortic stenosis. Ann Cardiothorac Surg (2013) 1.87
Emerging roles for phospholipase A2 enzymes in cancer. Biochimie (2010) 1.86
Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases: a critical appraisal of 48 cases. Ann Surg (2010) 1.79
Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis. Ann Surg Oncol (2008) 1.77
A systematic review and meta-analysis on pulmonary resections by robotic video-assisted thoracic surgery. Ann Cardiothorac Surg (2012) 1.75
Coronary artery bypass grafting with and without manipulation of the ascending aorta--a meta-analysis. Heart Lung Circ (2011) 1.70
Video-assisted thoracic surgery versus open thoracotomy for non-small cell lung cancer: a meta-analysis of propensity score-matched patients. Interact Cardiovasc Thorac Surg (2012) 1.70
Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer (2008) 1.67
HLA has strongest association with IgA nephropathy in genome-wide analysis. J Am Soc Nephrol (2010) 1.64
Critical assessment of risk factors for complications after cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol (2009) 1.63
Association of NCF2, IKZF1, IRF8, IFIH1, and TYK2 with systemic lupus erythematosus. PLoS Genet (2011) 1.59
Failure analysis of recurrent disease following complete cytoreduction and perioperative intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer. Ann Surg Oncol (2007) 1.56
Pulmonary radiofrequency ablation--an international study survey. Anticancer Res (2004) 1.54
A systematic review and meta-analysis on the safety and efficacy of the frozen elephant trunk technique in aortic arch surgery. Ann Cardiothorac Surg (2013) 1.53
Evolution of locoregional treatment for peritoneal carcinomatosis: single-center experience of 308 procedures of cytoreductive surgery and perioperative intraperitoneal chemotherapy. Am J Surg (2010) 1.51
Randomized crossover study evaluating the effect of gemcitabine infusion dose rate: evidence of auto-induction of gemcitabine accumulation. J Clin Oncol (2007) 1.50
Recurrence after complete cryoablation of colorectal liver metastases: analysis of prognostic features. Am Surg (2006) 1.49
Percutaneous radiofrequency ablation of pulmonary metastases from colorectal carcinoma: prognostic determinants for survival. Ann Surg Oncol (2006) 1.47
Secondary cytoreduction and perioperative intraperitoneal chemotherapy after initial debulking of pseudomyxoma peritonei: a study of timing and the impact of malignant dedifferentiation. J Am Coll Surg (2010) 1.47
Review of patients with peritoneal malignancy treated with peritonectomy and heated intraperitoneal chemotherapy. ANZ J Surg (2006) 1.47
Aortic valve-sparing operations in aortic root aneurysms: remodeling or reimplantation? Interact Cardiovasc Thorac Surg (2011) 1.47
Radiofrequency ablation as an adjunct to systemic chemotherapy for colorectal pulmonary metastases. Cancer (2010) 1.46
Surgical cytoreduction and survival in appendiceal cancer peritoneal carcinomatosis: an evaluation of 46 consecutive patients. Ann Surg Oncol (2011) 1.44
Video-assisted thoracic surgery versus open thoracotomy for non-small-cell lung cancer: a propensity score analysis based on a multi-institutional registry. Eur J Cardiothorac Surg (2013) 1.44
Radiofrequency ablation of lung tumors: feasibility and safety. Ann Thorac Surg (2009) 1.42
Hepatectomy and lung radiofrequency ablation for hepatic and subsequent pulmonary metastases from colorectal carcinoma. J Surg Oncol (2007) 1.41
Consensus statement on the loco-regional treatment of appendiceal mucinous neoplasms with peritoneal dissemination (pseudomyxoma peritonei). J Surg Oncol (2008) 1.41
Long-term outcome of hybrid surgical approach of video-assisted minithoracotomy sleeve lobectomy for non-small-cell lung cancer. Surg Endosc (2011) 1.40
A suture not always the ideal solution: problems encountered in developing a suture-based PFO closure technique. Catheter Cardiovasc Interv (2009) 1.40
A systematic review and meta-analysis of cytoreductive surgery with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol (2009) 1.37
Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy. J Thorac Oncol (2011) 1.35
A systematic review of extrapleural pneumonectomy for malignant pleural mesothelioma. J Thorac Oncol (2010) 1.34
Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option. Ann Surg Oncol (2009) 1.32
Presenting symptoms of epithelial ovarian cancer. Aust N Z J Obstet Gynaecol (2005) 1.31
Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer. Cancer Metastasis Rev (2012) 1.31
Defective removal of ribonucleotides from DNA promotes systemic autoimmunity. J Clin Invest (2014) 1.25
Systematic review of trimodality therapy for patients with malignant pleural mesothelioma. Ann Cardiothorac Surg (2012) 1.25
Towards randomized trials of cytoreductive surgery using peritonectomy and hyperthermic intraperitoneal chemotherapy for ovarian cancer peritoneal carcinomatosis. Gynecol Oncol (2009) 1.23
Hepatic resection for metastatic breast cancer: a systematic review. Eur J Cancer (2011) 1.21
Cytoreductive surgery and perioperative intraperitoneal chemotherapy for isolated colorectal peritoneal carcinomatosis: experimental therapy or standard of care? Ann Surg (2008) 1.20
A systematic review of radiofrequency ablation for lung tumors. Ann Surg Oncol (2008) 1.20
A meta-analysis of deep hypothermic circulatory arrest versus moderate hypothermic circulatory arrest with selective antegrade cerebral perfusion. Ann Cardiothorac Surg (2013) 1.19
Learning curve for cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal surface malignancy--a journey to becoming a Nationally Funded Peritonectomy Center. Ann Surg Oncol (2007) 1.15
Systematic review of randomized and nonrandomized trials of the clinical response and outcomes of neoadjuvant systemic chemotherapy for resectable colorectal liver metastases. Ann Surg Oncol (2009) 1.14
Diffuse malignant peritoneal mesothelioma--an update on treatment. Cancer Treat Rev (2011) 1.14
Urokinase plasminogen activator system as a potential target for cancer therapy. Future Oncol (2009) 1.13
Thromboembolic complications in patients with clear cell carcinoma of the ovary. Gynecol Oncol (2006) 1.12
HAX1 Augments Cell Proliferation, Migration, Adhesion, and Invasion Induced by Urokinase-Type Plasminogen Activator Receptor. J Oncol (2012) 1.12
Establishing evidence for change in ovarian cancer surgery--proposing clinical trials of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer peritoneal carcinomatosis. Gynecol Oncol (2009) 1.10
Cost-effectiveness of transcatheter aortic valve implantation versus surgery for high-risk patients with aortic stenosis. J Am Coll Cardiol (2013) 1.09
Long-term survival in patients with pseudomyxoma peritonei treated with cytoreductive surgery and perioperative intraperitoneal chemotherapy: 10 years of experience from a single institution. Ann Surg Oncol (2009) 1.08
Novel protein interactors of urokinase-type plasminogen activator receptor. Biochem Biophys Res Commun (2010) 1.07
Surgical management of melanoma lung metastasis: an analysis of survival outcomes in 292 consecutive patients. Ann Surg Oncol (2012) 1.07
Involvement of urokinase-type plasminogen activator system in cancer: an overview. Med Res Rev (2014) 1.06
Inhibitors of vascular endothelial growth factor in cancer. Cardiovasc Hematol Agents Med Chem (2008) 1.06
Surgical biology for the clinician: peritoneal mesothelioma: current understanding and management. Can J Surg (2009) 1.06
In-line radiofrequency ablation to minimize blood loss in hepatic parenchymal transection. Am J Surg (2005) 1.05
Summary of prognostic factors and patient selection for extrapleural pneumonectomy in the treatment of malignant pleural mesothelioma. Ann Surg Oncol (2011) 1.05
Percutaneous imaging-guided radiofrequency ablation in patients with colorectal pulmonary metastases: 1-year follow-up. Ann Surg Oncol (2004) 1.05
A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database*. Cancer (2010) 1.05
A meta-analysis comparing bilateral internal mammary artery with left internal mammary artery for coronary artery bypass grafting. Ann Cardiothorac Surg (2013) 1.03
Surgical metastasectomy in AJCC stage IV M1c melanoma patients with gastrointestinal and liver metastases. Ann Acad Med Singapore (2010) 1.03
Identification of SH2B2beta as an inhibitor for SH2B1- and SH2B2alpha-promoted Janus kinase-2 activation and insulin signaling. Endocrinology (2007) 1.03
Thoracic endovascular aortic repair--indications and evidence. Ann Thorac Cardiovasc Surg (2011) 1.03
Radioembolization versus standard care of hepatic metastases: comparative retrospective cohort study of survival outcomes and adverse events in salvage patients. J Vasc Interv Radiol (2011) 1.03
Systematic review of neoadjuvant transarterial chemoembolization for resectable hepatocellular carcinoma. Liver Int (2009) 1.01
Intrathoracic application of a vacuum-assisted closure device in managing pleural space infection after lung resection: is it an option? Interact Cardiovasc Thorac Surg (2011) 1.01
Radioembolization and chemoembolization for unresectable neuroendocrine liver metastases - a systematic review. Surg Oncol (2012) 1.01
Video-assisted thoracoscopic pneumonectomy: the Edinburgh posterior approach. Ann Cardiothorac Surg (2012) 1.01
Inhibition of the IL-6 signaling pathway: a strategy to combat chronic inflammatory diseases and cancer. Cytokine Growth Factor Rev (2012) 1.01
Exploring the role of resection of extrahepatic metastases from hepatocellular carcinoma. Surg Oncol (2011) 1.00